Targets › ABAT
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2028.
Catalyzes the conversion of gamma-aminobutyrate and L-beta-aminoisobutyrate to succinate semialdehyde and methylmalonate semialdehyde, respectively. Can also convert delta-aminovalerate and beta-alanine (By similarity). (UniProt, P80404)
Open in Phaseline: the race on ABAT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Katarzyna Kotulska | Vigabatrin Gamma-amino-N-butyrate transaminase inhibitor | ABAT | Phase 2 | Tuberous Sclerosis Complex | Dec 2028 |
Tuberous Sclerosis Complex (1)
small molecule (1)
Katarzyna Kotulska (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.